Answers are grounded in this paper and cite their sources.
Background Hyperuricemia (HUA), a metabolic disorder resulting from abnormalities in purine metabolism or impaired renal uric acid excretion, has shown a rising global prevalence. Although Chinese herbal medicine (CHM) exhibits therapeutic potential for HUA, strong evidence supporting its efficacy and safety remains limited. Objective This study aimed to systematically evaluate the efficacy and safety of oral CHM in lowering serum uric acid (SUA) levels. Methods Randomised controlled trials (RCTs) published between January 2013 and February 2024 were retrieved from PubMed, Embase, Cochrane Library, Web of Science, CNKI, CBM, and Wanfang databases. Meta-analyses were performed using Review Manager 5.4, along with sensitivity analyses, meta-regression, and subgroup analyses to explore heterogeneity. Study quality was assessed using the Cochrane Risk of Bias tool. Results A total of 53 RCTs involving 5 176 patients were included. CHM monotherapy or CHM combined with Western medicine (WM) significantly reduced SUA levels compared to WM alone (MD = −45.28, 95% CI: −55.06 to −35.50, P < 0.0001). Adverse events occurred in 8.79% of patients receiving CHM or CHM + WM, significantly lower than in the WM control group (RR = 0.63, 95% CI: 0.48–0.83, P = 0.0009). Conclusion Oral CHM shows significant efficacy and a favourable safety profile in reducing SUA levels, representing a promising alternative for HUA management. However, these findings require confirmation through large-scale, high-quality RCTs due to heterogeneity and methodological limitations in existing studies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: